Could a single gene shot replace monthly eye injections for wet AMD?

NCT ID NCT05657301

Ongoing Disease control Sponsor: Chengdu Origen Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for frequent eye injections. About 25 adults aged 50-85 who have previously responded to standard anti-VEGF therapy will receive a one-time dose to check safety and tolerability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Kanghong Investigative Site

Phoenix, Arizona, 85016, United States
Kanghong Investigative Site

Lemont, Illinois, 60439, United States
Kanghong Investigative Site

Boston, Massachusetts, 02114, United States
Kanghong Investigative Site

Reno, Nevada, 89502, United States
Kanghong Investigative Site

Cherry Hill, New Jersey, 08034, United States
Kanghong Investigative Site

Germantown, Tennessee, 38138, United States
Kanghong Investigative Site

Dallas, Texas, 75231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.